Experimental therapies for yellow fever

Antiviral Research

Volumn 97, Issue 2, 2013, Pages 169-179

  Julander, Justin G ^a  

^a UTAH STATE UNIVERSITY   (United States)

Author keywords

Antiviral therapy; Flavivirus; Yellow fever virus

Indexed keywords

17D VACCINE; BOCEPREVIR; FAVIPIRAVIR; IVERMECTIN; LIVE VACCINE; MONTIRELIN; NONSTRUCTURAL PROTEIN 1; NONSTRUCTURAL PROTEIN 4B; NONSTRUCTURAL PROTEIN 5; RIBAVIRIN; T 1106; TELAPREVIR; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; YELLOW FEVER VACCINE;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CHRONIC FATIGUE SYNDROME; COMPLEX FORMATION; DISEASE ASSOCIATION; DRUG SAFETY; EPIDEMIC; EXPERIMENTAL THERAPY; HEPATITIS C; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOPATHOGENESIS; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MENINGOENCEPHALITIS; MORTALITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; REPLICON; REVIEW; TICK BORNE ENCEPHALITIS FLAVIVIRUS; VIRUS CELL INTERACTION; VIRUS CLASSIFICATION; VIRUS REPLICATION; VIRUS RESISTANCE; XENOTROPIC MULV RELATED VIRUS; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS;

FLAVIVIRIDAE; FLAVIVIRUS; HEPATITIS C VIRUS; JAPANESE ENCEPHALITIS VIRUS; YELLOW FEVER VIRUS;

EID: 84871942750     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.12.002     Document Type: Review

References (111)

1. Anwar A., Hosoya T., Leong K.M., Onogi H., Okuno Y., Hiramatsu T., Koyama H., Suzuki M., Hagiwara M., Garcia-Blanco M.A. The kinase inhibitor SFV785 dislocates dengue virus envelope protein from the replication complex and blocks virus assembly. PloS One 2011, 6:e23246.
2. Avirutnan P., Fuchs A., Hauhart R.E., Somnuke P., Youn S., Diamond M.S., Atkinson J.P. Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. Journal of Experimental Medicine 2010, 207:793-806.
3. Avirutnan P., Hauhart R.E., Somnuke P., Blom A.M., Diamond M.S., Atkinson J.P. Binding of flavivirus nonstructural protein NS1-C4b binding protein modulates complement activation. Journal of Immunology 2011, 187:424-433.
4. Barrett A.D., Teuwen D.E. Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?. Current Opinion in Immunology 2009, 21:308-313.
5. Beigel J.H., Nordstrom J.L., Pillemer S.R., Roncal C., Goldwater D.R., Li H., Holland P.C., Johnson S., Stein K., Koenig S. Safety and pharmacokinetics of single intravenous dose of MGAWN1, a novel monoclonal antibody to West Nile virus. Antimicrobial Agents and Chemotherapy 2010, 54:2431-2436.
6. Bhatt P.N., Johnson E.A., Smith A.L., Jacoby R.O. Genetic resistance to lethal flaviviral encephalitis. III. Replication of Banzi virus in vitro and in vivo in tissues of congeneic susceptible and resistant mice. Archives of Virology 1981, 69:273-286.
7. Bhattacharya D., Ansari I.H., Striker R. The flaviviral methyltransferase is a substrate of Casein Kinase 1. Virus Research 2009, 141:101-104.
8. Bhattacharya D., Hoover S., Falk S.P., Weisblum B., Vestling M., Striker R. Phosphorylation of yellow fever virus NS5 alters methyltransferase activity. Virology 2008, 380:276-284.
9. Bollati M., Alvarez K., Assenberg R., Baronti C., Canard B., Cook S., Coutard B., Decroly E., de Lamballerie X., Gould E.A., Grard G., Grimes J.M., Hilgenfeld R., Jansson A.M., Malet H., Mancini E.J., Mastrangelo E., Mattevi A., Milani M., Moureau G., Neyts J., Owens R.J., Ren J., Selisko B., Speroni S., Steuber H., Stuart D.I., Unge T., Bolognesi M. Structure and functionality in flavivirus NS-proteins: perspectives for drug design. Antiviral Research 2010, 87:125-148.
10. Botting C., Kuhn R.J. Novel approaches to flavivirus drug discovery. Expert Opinion on Drug Discovery 2012, 7:417-428.
11. Bronzoni R.V., Madrid M.C., Duarte D.V., Pellegrini V.O., Pacca C.C., Carmo A.C., Zanelli C.F., Valentini S.R., Santacruz-Perez C., Barbosa J.A., Lutz C.S., Rahal P., Nogueira M.L. The small nuclear ribonucleoprotein U1A interacts with NS5 from yellow fever virus. Archives of Virology 2011, 156:931-938.
12. Buckwold V.E., Wei J., Huang Z., Huang C., Nalca A., Wells J., Russell J., Collins B., Ptak R., Lang W., Scribner C., Blanchett D., Alessi T., Langecker P. Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses. Antiviral Research 2007, 73:118-125.
13. Carroll S.S., Olsen D.B. Nucleoside analog inhibitors of hepatitis C virus replication. Infectious Disorders Drug Targets 2006, 6:17-29.
14. Day C.W., Smee D.F., Julander J.G., Yamshchikov V.F., Sidwell R.W., Morrey J.D. Error-prone replication of West Nile virus caused by ribavirin. Antiviral Research 2005, 67:38-45.
15. Deng Y.Q., Dai J.X., Ji G.H., Jiang T., Wang H.J., Yang H.O., Tan W.L., Liu R., Yu M., Ge B.X., Zhu Q.Y., Qin E.D., Guo Y.J., Qin C.F. A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein. PloS One 2011, 6:e16059.
16. Dong H., Zhang B., Shi P.Y. Flavivirus methyltransferase: a novel antiviral target. Antiviral Research 2008, 80:1-10.
17. Doyle, J.S., Aspinall, E., Liew, D., Thompson, A.J., Hellard, M.E., 2012. Current and emerging antiviral treatments for hepatitis C infection. British Journal of Clinical Pharmacology, http://dx.doi.org/10.1111/j.1365-2125.2012.04419.x.
18. Egloff M.P., Benarroch D., Selisko B., Romette J.L., Canard B. An RNA cap (nucleoside-2'-O-)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization. EMBO Journal 2002, 21:2757-2768.
19. El-Serag H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012, 142(1264-1273):e1261.
20. Eriksson B., Helgstrand E., Johansson N.G., Larsson A., Misiorny A., Noren J.O., Philipson L., Stenberg K., Stening G., Stridh S., Oberg B. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrobial Agents and Chemotherapy 1977, 11:946-951.
21. Fogt, J., Januszczyk, P., Framski, G., Onishi, T., Izawa, K., De Clercq, E., Neyts, J., Boryski, J., 2008. Synthesis and antiviral activity of novel derivatives of 2'-beta-C-methylcytidine. Nucleic Acids Symposium Series (Oxford), pp. 605-606.
22. Funk A., Truong K., Nagasaki T., Torres S., Floden N., Balmori Melian E., Edmonds J., Dong H., Shi P.Y., Khromykh A.A. RNA structures required for production of subgenomic flavivirus RNA. Journal of Virology 2010, 84:11407-11417.
23. Furuta Y., Takahashi K., Shiraki K., Sakamoto K., Smee D.F., Barnard D.L., Gowen B.B., Julander J.G., Morrey J.D. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Research 2009, 82:95-102.
24. Gowen B.B., Julander J.G., London N.R., Wong M.H., Larson D., Morrey J.D., Li D.Y., Bray M. Assessing changes in vascular permeability in a hamster model of viral hemorrhagic fever. Virology Journal 2010, 7:240.
25. Greenstone H., Spinelli B., Tseng C., Peacock S., Taylor K., Laughlin C. NIAID resources for developing new therapies for severe viral infections. Antiviral Research 2008, 78:51-59.
26. Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold?. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2009, 48(Suppl. 1):S3-S13.
27. Heinz F.X., Stiasny K. Flaviviruses and flavivirus vaccines. Vaccine 2012, 30:4301-4306.
28. Holzmann I., Agostini I., Areta J.I., Ferreyra H., Beldomenico P., Di Bitetti M.S. Impact of yellow fever outbreaks on two howler monkey species (Alouatta guariba clamitans and A. caraya) in Misiones, Argentina. American Journal of Primatology 2010, 72:475-480.
29. Ilyas J.A., Vierling J.M. An overview of emerging therapies for the treatment of chronic hepatitis C. Clinics in Liver Disease 2011, 15:515-536.
30. Julander J.G., Ennis J., Turner J., Morrey J.D. Treatment of yellow fever virus with an adenovirus-vectored interferon (DEF201) in a hamster model. Antimicrobial agents and chemotherapy 2011, 55:2067-2073.
31. Julander J.G., Furuta Y., Shafer K., Sidwell R.W. Activity of T-1106 in a hamster model of yellow Fever virus infection. Antimicrobial Agents and Chemotherapy 2007, 51:1962-1966.
32. Julander J.G., Jha A.K., Choi J.A., Jung K.H., Smee D.F., Morrey J.D., Chu C.K. Efficacy of 2'-C-methylcytidine against yellow fever virus in cell culture and in a hamster model. Antiviral Research 2010, 86:261-267.
33. Julander J.G., Judge J.W., Olsen A.L., Rosenberg B., Schafer K., Sidwell R.W. Prophylactic treatment with recombinant Eimeria protein, alone or in combination with an agonist cocktail, protects mice from Banzi virus infection. Antiviral Research 2006, 75:14-19.
34. Julander J.G., Morrey J.D., Blatt L.M., Shafer K., Sidwell R.W. Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster model. Antiviral Research 2007, 73:140-146.
35. Julander J.G., Shafer K., Smee D.F., Morrey J.D., Furuta Y. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrobial Agents and Chemotherapy 2009, 53:202-209.
36. Julander J.G., Trent D.W., Monath T.P. Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. Vaccine 2011, 29:6008-6016.
37. Kannappan P., Narayanan S. Mutation and docking studies on NS2b-NS3 complex from yellow fever virus towards drug discovery. Bioinformation 2011, 6:303-306.
38. Kay A., Chen L.H., Sisti M., Monath T.P. Yellow fever vaccine seroconversion in travelers. American Journal of Tropical Medicine and Hygiene 2011, 85:748-749.
39. Kuhn S., Twele-Montecinos L., MacDonald J., Webster P., Law B. Case report: probable transmission of vaccine strain of yellow fever virus to an infant via breast milk. Canadian Medical Association Journal 2011, 183:E243-E245.
40. Kumar R., Tripathi P., Baranwal M., Singh S., Tripathi S., Banerjee G. Randomized, controlled trial of oral ribavirin for Japanese encephalitis in children in Uttar Pradesh, India. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2009, 48:400-406.
41. Lam A.M., Murakami E., Espiritu C., Steuer H.M., Niu C., Keilman M., Bao H., Zennou V., Bourne N., Julander J.G., Morrey J.D., Smee D.F., Frick D.N., Heck J.A., Wang P., Nagarathnam D., Ross B.S., Sofia M.J., Otto M.J., Furman P.A. PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrobial Agents and Chemotherapy 2010, 54:3187-3196.
42. Lasala P.R., Holbrook M. Tick-borne flaviviruses. Clinics in Laboratory Medicine 2010, 30:221-235.
43. Le Breton M., Meyniel-Schicklin L., Deloire A., Coutard B., Canard B., de Lamballerie X., Andre P., Rabourdin-Combe C., Lotteau V., Davoust N. Flavivirus NS3 and NS5 proteins interaction network: a high-throughput yeast two-hybrid screen. BMC Microbiology 2011, 11:234.
44. Leyssen P., De Clercq E., Neyts J. The anti-yellow fever virus activity of ribavirin is independent of error-prone replication. Molecular Pharmacology 2006, 69:1461-1467.
45. Li G., Duan T., Wu X., Tesh R.B., Soong L., Xiao S.Y. Yellow fever virus infection in Syrian golden hamsters: relationship between cytokine expression and pathologic changes. International Journal of Clinical and Experimental Pathology 2008, 1:169-179.
46. Lim P.Y., Keating J.A., Hoover S., Striker R., Bernard K.A. A thiopurine drug inhibits West Nile virus production in cell culture, but not in mice. PloS One 2011, 6:e26697.
47. Liu L., Dong H., Chen H., Zhang J., Ling H., Li Z., Shi P.Y., Li H. Flavivirus RNA cap methyltransferase: structure, function, and inhibition. Frontiers in Biology 2010, 5:286-303.
48. Martinez M.J., Vilella A., Pumarola T., Roldan M., Sequera V.G., Vera I., Hayes E.B. Persistence of yellow fever vaccine RNA in urine. Vaccine 2011, 29:3374-3376.
49. Mastrangelo E., Pezzullo M., De Burghgraeve T., Kaptein S., Pastorino B., Dallmeier K., de Lamballerie X., Neyts J., Hanson A.M., Frick D.N., Bolognesi M., Milani M. Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug 2012, Journal of Antimicrobial Chemotherapy.
50. Maximova O.A., Ward J.M., Asher D.M., St Claire M., Finneyfrock B.W., Speicher J.M., Murphy B.R., Pletnev A.G. Comparative neuropathogenesis and neurovirulence of attenuated flaviviruses in nonhuman primates. Journal of Virology 2008, 82:5255-5268.
51. Mayhoub A.S., Khaliq M., Kuhn R.J., Cushman M. Design, synthesis, and biological evaluation of thiazoles targeting flavivirus envelope proteins. Journal of Medicinal Chemistry 2011, 54:1704-1714.
52. McMullan L.K., Frace M., Sammons S.A., Shoemaker T., Balinandi S., Wamala J.F., Lutwama J.J., Downing R.G., Stroeher U., MacNeil A., Nichol S.T. Using next generation sequencing to identify yellow fever virus in Uganda. Virology 2012, 422:1-5.
53. Meier K.C., Gardner C.L., Khoretonenko M.V., Klimstra W.B., Ryman K.D. A mouse model for studying viscerotropic disease caused by yellow fever virus infection. PLoS Pathology 2009, 5:e1000614.
54. Meneses R., Ocazionez R.E., Martinez J.R., Stashenko E.E. Inhibitory effect of essential oils obtained from plants grown in Colombia on yellow fever virus replication in vitro. Annals of Clinical Microbiology and Antimicrobials 2009, 8:8.
55. Monath T.P. Treatment of yellow fever. Antiviral Research 2008, 78:116-124.
56. Monath T.P., Brinker K.R., Chandler F.W., Kemp G.E., Cropp C.B. Pathophysiologic correlations in a rhesus monkey model of yellow fever with special observations on the acute necrosis of B cell areas of lymphoid tissues. American Journal of Tropical Medicine and Hygiene 1981, 30:431-443.
57. Monath T.P., Fowler E., Johnson C.T., Balser J., Morin M.J., Sisti M., Trent D.W. An inactivated cell-culture vaccine against yellow fever. New England Journal of Medicine 2011, 364:1326-1333.
58. Monath T.P., Lee C.K., Julander J.G., Brown A., Beasley D.W., Watts D.M., Hayman E., Guertin P., Makowiecki J., Crowell J., Levesque P., Bowick G.C., Morin M., Fowler E., Trent D.W. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine 2010, 28:3827-3840.
59. Monath T.P., Nichols R., Archambault W.T., Moore L., Marchesani R., Tian J., Shope R.E., Thomas N., Schrader R., Furby D., Bedford P. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. American Journal of Tropical Medicine and Hygiene 2002, 66:533-541.
60. Morrey J.D., Siddharthan V., Olsen A.L., Roper G.Y., Wang H., Baldwin T.J., Koenig S., Johnson S., Nordstrom J.L., Diamond M.S. Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters. Journal of Infectious Diseases 2006, 194:1300-1308.
61. Morrey J.D., Siddharthan V., Olsen A.L., Wang H., Julander J.G., Hall J.O., Li H., Nordstrom J.L., Koenig S., Johnson S., Diamond M.S. Defining limits of humanized neutralizing monoclonal antibody treatment for West Nile virus neurological infection in a hamster model. Antimicrobial Agents and Chemotherapy 2007, 51:2396-2402.
62. Muller V.D., Russo R.R., Oliveira Cintra A.C., Sartim M.A., De Melo Alves-Paiva R., Figueiredo L.T., Sampaio S.V., Aquino V.H. Crotoxin and phospholipases A(2) from Crotalus durissus terrificus showed antiviral activity against dengue and yellow fever viruses. Toxicon 2012, 59:507-515.
63. Nair V., Chi G., Shu Q., Julander J., Smee D.F. A heterocyclic molecule with significant activity against dengue virus. Bioorganic and Medicinal Chemistry Letters 2009, 19:1425-1427.
64. Nguyet, N.M., Chau, T.N., Lam, P.K., Kien, D.T., Huy, H.L., Farrar, J., Quyen, T.H., Hien, T.T., Van Vinh Chau, N., Merson, L., Long, H.T., Hibberd, M.L., Aw, P.P., Wilm, A., Nagarajan, N., Dung, N.T., Mai, P.P., Truong, N.T., Javanbaht, H., Klumpp, K., Hammond, J., Petric, R., Wolbers, M., Chinh, N.T., Simmons, C.P., 2012. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. Journal of Infectious Diseases, http://dx.doi.org/10.1093/infdis/jis470.
65. Nunes F.P., Zychar B.C., Della-Casa M.S., Sampaio S.C., Goncalves L.R., Cirillo M.C. Crotoxin is responsible for the long-lasting anti-inflammatory effect of Crotalus durissus terrificus snake venom: involvement of formyl peptide receptors. Toxicon 2010, 55:1100-1106.
66. Pacanowski J., Lacombe K., Campa P., Dabrowska M., Poveda J.D., Meynard J.L., Poirot J.L., Fonquernie L., Girard P.M. Plasma HIV-RNA is the key determinant of long-term antibody persistence following Yellow fever immunization in a cohort of 364 HIV-infected patients 2012, Journal of Acquired Immune Deficiency Syndromes.
67. Pacca C.C., Severino A.A., Mondini A., Rahal P., D'Avila S.G., Cordeiro J.A., Nogueira M.C., Bronzoni R.V., Nogueira M.L. RNA interference inhibits yellow fever virus replication in vitro and in vivo. Virus Genes 2009, 38:224-231.
68. Patkar C.G., Kuhn R.J. Yellow Fever virus NS3 plays an essential role in virus assembly independent of its known enzymatic functions. Journal of Virology 2008, 82:3342-3352.
69. Patkar C.G., Larsen M., Owston M., Smith J.L., Kuhn R.J. Identification of inhibitors of yellow fever virus replication using a replicon-based high-throughput assay. Antimicrobial Agents and Chemotherapy 2009, 53:4103-4114.
70. Paula T., Pablo R., Eugenia V., Pablo B., Sabino P., Jose M., Antonio M., Dolores H.M., Pablo L., Javier G.S., Vincente S. New drug targets for hepatitis C and other Flaviviridae viruses. Infectious Disorders Drug Targets 2009, 9:133-147.
71. Peduto A., Massa A., Di Mola A., de Caprariis P., La Colla P., Loddo R., Altamura S., Maga G., Filosa R. 2,3-Dihydro-1,2-diphenyl-substituted 4H-Pyridinone derivatives as new anti Flaviviridae inhibitors. Chemical Biology and Drug Design 2011, 77:441-449.
72. Pierra C., Amador A., Benzaria S., Cretton-Scott E., D'Amours M., Mao J., Mathieu S., Moussa A., Bridges E.G., Standring D.N., Sommadossi J.P., Storer R., Gosselin G. Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine. Journal of Medicinal Chemistry 2006, 49:6614-6620.
73. Pierson T.C., Diamond M.S. Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Reviews in Molecular Medicine 2008, 10:e12.
74. Pires-Marczeski F.C., Martinez V.P., Nemirovsky C., Padula P.J. Intrathecal antibody production in two cases of yellow fever vaccine associated neurotropic disease in Argentina. Journal of Medical Virology 2011, 83:2208-2212.
75. Ray D., Shah A., Tilgner M., Guo Y., Zhao Y., Dong H., Deas T.S., Zhou Y., Li H., Shi P.Y. West Nile virus 5'-cap structure is formed by sequential guanine N-7 and ribose 2'-O methylations by nonstructural protein 5. Journal of Virology 2006, 80:8362-8370.
76. Rosen H.R. Clinical practice. Chronic hepatitis C infection. New England Journal of Medicine 2011, 364:2429-2438.
77. Sbrana E., Xiao S.Y., Guzman H., Ye M., Travassos da Rosa A.P., Tesh R.B. Efficacy of post-exposure treatment of yellow fever with ribavirin in a hamster model of the disease. American Journal of Tropical Medicine and Hygiene 2004, 71:306-312.
78. Sbrana E., Xiao S.Y., Popov V.L., Newman P.C., Tesh R.B. Experimental yellow fever virus infection in the golden hamster (Mesocricetus auratus) III. Clinical laboratory values. American Journal of Tropical Medicine and Hygiene 2006, 74:1084-1089.
79. Schafer B., Holzer G.W., Joachimsthaler A., Coulibaly S., Schwendinger M., Crowe B.A., Kreil T.R., Barrett P.N., Falkner F.G. Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever. PloS One 2011, 6:e24505.
80. Schoggins J.W., Wilson S.J., Panis M., Murphy M.Y., Jones C.T., Bieniasz P., Rice C.M. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011, 472:481-485.
81. Schuessler A., Funk A., Lazear H.M., Cooper D.A., Torres S., Daffis S., Jha B.K., Kumagai Y., Takeuchi O., Hertzog P., Silverman R., Akira S., Barton D.J., Diamond M.S., Khromykh A.A. West Nile virus non-coding subgenomic RNA contributes to viral evasion of type I interferon-mediated antiviral response 2012, Journal of Virology.
82. Seligman S.J. Yellow fever virus vaccine-associated deaths in young women. Emerging Infectious Diseases 2011, 17:1891-1893.
83. Shimoni Z., Niven M.J., Pitlick S., Bulvik S. Treatment of West Nile virus encephalitis with intravenous immunoglobulin. Emerging Infectious Diseases 2001, 7:759.
84. Simmons C.P., Farrar J.J., Nguyen v.V., Wills B. Dengue. New England Journal of Medicine 2012, 366:1423-1432.
85. Smee D.F., McKernan P.A., Nord L.D., Willis R.C., Petrie C.R., Riley T.M., Revankar G.R., Robins R.K., Smith R.A. Novel pyrazolo[3,4-d]pyrimidine nucleoside analog with broad-spectrum antiviral activity. Antimicrobial Agents and Chemotherapy 1987, 31:1535-1541.
86. Smithburn K.C., Paterson H.E., Heymann C.S., Winter P.A. An agent related to Uganda S virus from man and mosquitoes in South Africa. South African Medical Journal 1959, 33:959-962.
87. Stapleton J.T., Foung S., Muerhoff A.S., Bukh J., Simmonds P. The GB viruses: a review and proposed classification of GBV-A, GBV-C (HGV), and GBV-D in genus Pegivirus within the family Flaviviridae. Journal of General Virology 2011, 92:233-246.
88. Stein D.A., Shi P.Y. Nucleic acid-based inhibition of flavivirus infections. Frontiers in Bioscience 2008, 13:1385-1395.
89. Stock N.K., Boschetti N., Herzog C., Appelhans M.S., Niedrig M. The phylogeny of yellow fever virus 17D vaccines. Vaccine 2012, 30:989-994.
90. Stuyver L.J., McBrayer T.R., Tharnish P.M., Clark J., Hollecker L., Lostia S., Nachman T., Grier J., Bennett M.A., Xie M.Y., Schinazi R.F., Morrey J.D., Julander J.G., Furman P.A., Otto M.J. Inhibition of hepatitis C replicon RNA synthesis by beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication. Antiviral Chemistry and Chemotherapy 2006, 17:79-87.
91. Switzer W.M., Zheng H., Simmons G., Zhou Y., Tang S., Shankar A., Kapusinszky B., Delwart E.L., Heneine W. No evidence of murine leukemia virus-related viruses in live attenuated human vaccines. PloS One 2011, 6:e29223.
92. Tesh R.B., Guzman H., da Rosa A.P., Vasconcelos P.F., Dias L.B., Bunnell J.E., Zhang H., Xiao S.Y. Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies. Journal of Infectious Diseases 2001, 183:1431-1436.
93. Thibodeaux B.A., Garbino N.C., Liss N.M., Piper J., Blair C.D., Roehrig J.T. A small animal peripheral challenge model of yellow fever using interferon-receptor deficient mice and the 17D-204 vaccine strain. Vaccine 2012, 30:3180-3187.
94. Thomas R.E., Lorenzetti D.L., Spragins W., Jackson D., Williamson T. The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review. American Journal of Tropical Medicine and Hygiene 2012, 86:359-372.
95. Throsby M., Geuijen C., Goudsmit J., Bakker A.Q., Korimbocus J., Kramer R.A., Clijsters-van der Horst M., de Jong M., Jongeneelen M., Thijsse S., Smit R., Visser T.J., Bijl N., Marissen W.E., Loeb M., Kelvin D.J., Preiser W., ter Meulen J., de Kruif J. Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus. Journal of Virology 2006, 80:6982-6992.
96. Traiber C., Coelho-Amaral P., Ritter V.R., Winge A. Infant meningoencephalitis caused by yellow fever vaccine virus transmitted via breastmilk. Journal of Pediatric (Rio de Janeiro) 2011, 87:269-272.
97. Tricou V., Minh N.N., Van T.P., Lee S.J., Farrar J., Wills B., Tran H.T., Simmons C.P. A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS Neglected Tropical Diseases 2010, 4:e785.
98. Turtle L., Griffiths M.J., Solomon T. Encephalitis caused by flaviviruses. QJM 2012, 105:219-223.
99. Umamaheswari A., Kumar M.M., Pradhan D., Marisetty H. Docking studies towards exploring antiviral compounds against envelope protein of yellow fever virus. Interdisciplinary Sciences 2011, 3:64-77.
100. Veit O., Niedrig M., Chapuis-Taillard C., Cavassini M., Mossdorf E., Schmid P., Bae H.G., Litzba N., Staub T., Hatz C., Furrer H. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2009, 48:659-666.
101. Vermehren J., Sarrazin C. New hepatitis C therapies in clinical development. European Journal of Medical Research 2011, 16:303-314.
102. Whittembury A., Ramirez G., Hernandez H., Ropero A.M., Waterman S., Ticona M., Brinton M., Uchuya J., Gershman M., Toledo W., Staples E., Campos C., Martinez M., Chang G.J., Cabezas C., Lanciotti R., Zaki S., Montgomery J.M., Monath T., Hayes E. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine 2009, 27:5974-5981.
103. Wiggan O., Livengood J.A., Silengo S.J., Kinney R.M., Osorio J.E., Huang C.Y., Stinchcomb D.T. Novel formulations enhance the thermal stability of live-attenuated flavivirus vaccines. Vaccine 2011, 29:7456-7462.
104. Wilckens V., Kannengiesser K., Hoxhold K., Frenkel C., Kucharzik T., Maaser C. The immunization status of patients with IBD is alarmingly poor before the introduction of specific guidelines. Scandinavian Journal of Gastroenterology 2011, 46:855-861.
105. Williams M.C., Woodall J.P. An epidemic of an illness resembling dengue in the Morogoro District of Tanganyika. East African Medical Journal 1964, 41:271-275.
106. Woodson S.E., Freiberg A.N., Holbrook M.R. Differential cytokine responses from primary human Kupffer cells following infection with wild-type or vaccine strain yellow fever virus. Virology 2011, 412:188-195.
107. Woodson S.E., Holbrook M.R. Infection of hepatocytes with 17-D vaccine-strain yellow fever virus induces a strong pro-inflammatory host response. Journal of General Virology 2011, 92:2262-2271.
108. Xiao S.Y., Zhang H., Guzman H., Tesh R.B. Experimental yellow fever virus infection in the Golden hamster (Mesocricetus auratus). II. Pathology. Journal of Infectious Diseases 2001, 183:1437-1444.
109. Xie X., Wang Q.Y., Xu H.Y., Qing M., Kramer L., Yuan Z., Shi P.Y. Inhibition of dengue virus by targeting viral NS4B protein. Journal of Virology 2011, 85:11183-11195.
110. Yin Z., Chen Y.L., Schul W., Wang Q.Y., Gu F., Duraiswamy J., Kondreddi R.R., Niyomrattanakit P., Lakshminarayana S.B., Goh A., Xu H.Y., Liu W., Liu B., Lim J.Y., Ng C.Y., Qing M., Lim C.C., Yip A., Wang G., Chan W.L., Tan H.P., Lin K., Zhang B., Zou G., Bernard K.A., Garrett C., Beltz K., Dong M., Weaver M., He H., Pichota A., Dartois V., Keller T.H., Shi P.Y. An adenosine nucleoside inhibitor of dengue virus. Proceedings of the National Academy of Sciences USA 2009, 106:20435-20439.
111. Zhou Y., Ray D., Zhao Y., Dong H., Ren S., Li Z., Guo Y., Bernard K.A., Shi P.Y., Li H. Structure and function of flavivirus NS5 methyltransferase. Journal of Virology 2007, 81:3891-3903.